GlassScriptPhysician profile
Ragui W Sadek
NPI 1235213679
$95,639.11
in general payments reported to CMS, 2019-2025
12 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $914 · 2021: $12K · 2022: $17K · 2023: $1,263 · 2024: $21K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $55K · Travel and Lodging: $7,905 · Food and Beverage: $2,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $54,810.00 |
| Travel and Lodging | $7,904.65 |
| Food and Beverage | $2,168.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $41,881.98 | 2021-2025 | Linx Reflux Management System |
| Ethicon INC. | $38,014.12 | 2021-2025 | Echelon; Endopath |
| Ethicon US, LLC | $9,486.87 | 2019-2025 | Echelon; Endopath, Linx Reflux Management System, Echelon Flex |
| Stryker Corporation | $3,467.84 | 2021-2023 | 1688 |
| Intuitive Surgical, INC. | $1,800.98 | 2019-2024 | |
| Medtronic, INC. | $441.39 | 2022-2024 | Signia, Endoflip |
| Baxter Healthcare | $185.96 | 2023-2025 | Floseal |
| Tela Bio, INC. | $145.86 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Boston Scientific Corporation | $134.31 | 2020-2021 | |
| Reshape Lifesciences INC. | $48.80 | 2023 | |
| Davol INC. | $16.18 | 2019 | |
| Novo Nordisk INC | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ragui Sadek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.